CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately. Mr. Gover has more than 25 years of leadership experience in the biotechnology industry. He served as the founding Chief Executive Officer of GW Pharmaceuticals plc, guiding the company for over two ...

CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. Th ...

Company Overview - Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases [3] - The company utilizes a platform of GeneTAC gene targeted chimera small molecules to modulate the expression of disease-causing genes [3] Upcoming Presentation - Management will present at the 2025 Jefferies Global Healthcare Conference on June 4, 2025, at 2:35 p.m. ET in New York [1] - A live webcast of the presentation will be available on the company's website and archived for at least 30 days [2] Product Development - The company is advancing clinical-stage programs including DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy [3] - Additional programs are in development for myotonic dystrophy type-1 and Huntington's disease, with ongoing discovery efforts for multiple genomic medicines [3]

Core Insights - Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases [3] - The company will participate in a fireside chat at the 2025 RBC Capital Markets Healthcare Conference on May 20, 2025 [1] - A live webcast of the event will be available and archived for at least 30 days [2] Company Overview - Design Therapeutics is developing a new class of therapies using its GeneTAC platform, which targets specific disease-causing genes [3] - Current clinical-stage programs include DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy, along with programs for myotonic dystrophy type-1 and Huntington's disease [3] - The company is also engaged in discovery efforts for multiple genomic medicines [3]